Accepted Manuscript

A platform for preparing homogeneous proteinaceous sub-visible particles with distinct morphologies

Malthe Møhl Schack, Eva Horn Møller, John F. Carpenter, Thomas Rades, Minna Groenning

PII: S0022-3549(18)30154-0

DOI: 10.1016/j.xphs.2018.03.014

Reference: XPHS 1109

To appear in: Journal of Pharmaceutical Sciences

Received Date: 9 September 2017

Revised Date: 23 January 2018

Accepted Date: 8 March 2018

Please cite this article as: Schack MM, Møller EH, Carpenter JF, Rades T, Groenning M, A platform for preparing homogeneous proteinaceous sub-visible particles with distinct morphologies, *Journal of Pharmaceutical Sciences* (2018), doi: 10.1016/j.xphs.2018.03.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



A platform for preparing homogeneous proteinaceous sub-visible particles with distinct morphologies

Malthe Møhl Schack^{a,b}, Eva Horn Møller^b, John F. Carpenter^c, Thomas Rades^a, Minna Groenning^{b,†}

^{a.} Department of Pharmacy, Section of Pharmaceutical Design and Drug Delivery, University of Copenhagen, Copenhagen, Denmark. ^{b.} Novo Nordisk A/S, Måløv, Denmark.

^c Department of Pharmaceutical Sciences, University of Colorado-Denver, Aurora, Colorado.

[†] Corresponding author. Email: mgqj@novonordisk.com

Regulatory authorities and scientific communities are increasingly attentive to the known and universal presence of small particulates in biological drug products. The underlying concern is that these particulates may cause unwanted formation of anti-drug antibodies in patients Pharmacological studies, however, have to date not succeeded in unambiguously identifying risk-prone particle properties. This lack of success may be partly due to a lack of available, well-defined, homogenous particle material. Protein particles arising from stress of protein drug products are by nature often highly heterogeneous in size, morphology, and structure of the constituent protein in the particles. Here, we present simple and pharmaceutically relevant stress conditions to produce eight different highly homogenous micrometre-sized protein particles from human insulin, representing very different morphologies and conformation of the constituent protein molecules in the particles generated. Insulin's self-association patterns were varied by formulation approaches to create diverse starting materials. The resulting collection of homogenous particles underlines that the particle formation is not necessarily a random process but a consequence of formulation and specific stress condition. Due to the inherent homogenicity of these populations, the particle materials can act as a standard platform for further studies on sub-visible particles in insulin drug products.

Download English Version:

https://daneshyari.com/en/article/8513194

Download Persian Version:

https://daneshyari.com/article/8513194

Daneshyari.com